Xeris Pharmaceuticals (XERS) AI Stock Analysis

• Market Cap: $1.26B
• Dividend Yield: N/A
• Average Volume (3M): 2.87M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 35.62%
• EPS Growth: 49.58%
• Country: US
• Employees: 394
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 161,480,360
• 10 Day Avg. Volume: 2,104,582
• 30 Day Avg. Volume: 2,872,178
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 3.83
• Enterprise Value/Gross Profit: 4.72
• Enterprise Value/Ebitda: 127.50
• 1Y Price Target: $9.00
• Price Target Upside: 14.80% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 55 Neutral
• Price Target: $7.50 ▼(-4.34% Downside)

The overall stock score is primarily influenced by the company's strong revenue growth and positive earnings call, which highlighted significant product demand and an upward revision in revenue guidance. However, financial performance challenges, including high leverage and negative equity, along with valuation concerns, weigh heavily on the score. Technical analysis shows bullish momentum, but caution is advised due to overbought indicators.

Positive Factors

Clinical Advancements

Significant clinical validation following Corcept's positive CATALYST trial readout.

Product Penetration

Stronger-than-expected Recorlev volume growth driven by increased penetration into the difficult-to-control type-2 diabetes market.

Revenue Growth

Xeris delivered strong revenues representing a robust growth, demonstrating management's increased confidence in their outlook and presenting a favorable setup for investors.

Negative Factors

Competition Impact

Keveyis faced a modest revenue decrease due to generic competition, though the addition of new patients helped slow the decline.

Execution Risks

Acknowledgement of execution risks given the nascent recognition of this patient population.

Xeris Pharmaceuticals Business Overview & Revenue Model

Company Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Xeris Pharmaceuticals generates revenue primarily through the sales of its products, particularly Gvoke, which is marketed for the emergency treatment of severe hypoglycemia in patients with diabetes. The company also earns revenue through partnerships and collaborations with other pharmaceutical companies, which may include licensing agreements, milestone payments, and royalties from product sales. Additionally, Xeris may explore opportunities in research and development agreements that can provide further financial support through funding or shared revenues from new therapies developed using its proprietary technology.

Xeris Pharmaceuticals Financial Statement Overview

Summary

Xeris Pharmaceuticals is experiencing revenue growth but faces significant profitability and cash flow challenges. The high leverage and negative equity position present financial risks. While revenue is increasing, the company needs to address its cost structure and improve cash flow management to enhance financial health.

Income Statement

Xeris Pharmaceuticals has shown a positive revenue growth rate of 10.55% in the TTM, indicating a growing top line. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased significantly from 81.86% in 2024 to 37.11% in the TTM, reflecting increased cost pressures or pricing challenges.

Balance Sheet

The balance sheet reveals high leverage with a negative equity position, resulting in a concerning debt-to-equity ratio of -13.32 in the TTM. The negative return on equity indicates that the company is not generating profits from its equity base, posing a risk to financial stability.

Cash Flow

Cash flow analysis shows a significant decline in free cash flow growth by -75.8% in the TTM, indicating cash management challenges. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. However, the free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2023	Dec 2023	Dec 2023
Income Statement
Total Revenue	246.03M	203.07M	163.91M	163.91M	163.91M	163.91M
Gross Profit	199.62M	166.24M	135.27M	135.27M	135.27M	135.27M
EBITDA	7.39M	-11.30M	-23.73M	-23.73M	-23.73M	-23.73M
Net Income	-32.00M	-54.84M	-62.26M	-62.26M	-62.26M	-62.26M
Balance Sheet
Total Assets	334.69M	323.06M	322.60M	322.60M	322.60M	322.60M
Cash, Cash Equivalents and Short-Term Investments	59.28M	71.62M	72.45M	72.45M	72.45M	72.45M
Total Debt	257.22M	271.45M	229.19M	229.19M	229.19M	229.19M
Total Liabilities	353.99M	352.68M	329.38M	329.38M	329.38M	329.38M
Stockholders Equity	-19.30M	-29.61M	-6.78M	-6.78M	-6.78M	-6.78M
Cash Flow
Free Cash Flow	-6.64M	-37.85M	-49.29M	-49.29M	-49.29M	-49.29M
Operating Cash Flow	-6.33M	-36.98M	-47.02M	-47.02M	-47.02M	-47.02M
Investing Cash Flow	19.64M	4.88M	-6.00M	-6.00M	-6.00M	-6.00M
Financing Cash Flow	-1.88M	36.17M	-1.61M	-1.61M	-1.61M	-1.61M

Xeris Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Positive. The current price of 7.84 is above the 20-day moving average (MA) of 7.43, above the 50-day MA of 6.00, and above the 200-day MA of 4.56, indicating a bullish trend. The MACD of 0.59 indicates Positive momentum. The RSI at 73.55 is Negative, neither overbought nor oversold. The STOCH value of 74.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XERS.

Xeris Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZYME	60 Neutral	$1.12B	―	-19.89%	―	95.94%	35.69%
XERS	55 Neutral	$1.26B	―	222.83%	―	35.62%	49.58%
Sector *	51 Neutral	$7.89B	-0.33	-41.61%	2.23%	23.26%	-2.03%
NRIX	47 Neutral	$696.45M	―	-50.67%	―	41.86%	10.48%
PRAX	47 Neutral	$958.42M	―	-60.98%	―	338.45%	-19.64%
XNCR	46 Neutral	$579.86M	―	-29.22%	―	-2.07%	22.52%
ABCL	42 Neutral	$1.25B	―	-15.64%	―	-0.54%	-6.28%

Xeris Pharmaceuticals Corporate Events

Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting

On June 4, 2025, Xeris Biopharma Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made. Three individuals were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The stockholders also approved the compensation of the Company’s Named Executive Officers on a non-binding advisory basis.

Xeris Pharmaceuticals Hosts Analyst and Investor Day

Xeris Pharmaceuticals announced its first Analyst and Investor Day scheduled for June 3, 2025, in New York City, where senior management will discuss the company’s growth strategy and financial outlook. The event aims to highlight the potential of products like Recorlev® and XP-8121, emphasizing their expected impact on revenue growth and the treatment landscape for conditions such as hypothyroidism, potentially affecting stakeholders by demonstrating the company’s commitment to long-term value creation.